GT Biopharma (GTBP) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Vistagen Therapeutics (VTGN) over the past year, gaining 451.9% versus a loss of 93.9%. Over five years, GTBP leads with a -96.7% price change compared with -99.7% for VTGN. GT Biopharma is the larger company by market cap ($11.3 million vs $10.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | VTGN |
|---|---|---|
| Share price | $6.27 | $0.2375 |
| Market cap | $11.30M | $10.54M |
| 1-day change | +5.39% | -3.53% |
| YTD return | +659.24% | -62.70% |
| 1-year return | +451.85% | -93.88% |
| 5-year return | -96.72% | -99.66% |
| EPS (TTM) | $-147.50 | $-1.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $5.14 |
| 52-week low | $4.91 | $0.20 |
| Distance from 52-week high | -78.21% | -95.38% |
| Analyst consensus | none | none |
| Avg. price target upside | +1097.07% | +321.05% |
| Average volume | 55.52K | 12.36M |
| Shares outstanding | 1.80M | 44.38M |
| Employees | 1 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed VTGN by 545.7 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
GTBP vs VTGN FAQ
Which is bigger, GT Biopharma or Vistagen Therapeutics?
GT Biopharma (GTBP) is larger, with a market capitalization of $11.30M compared with $10.54M for Vistagen Therapeutics (VTGN).
Which stock has performed better over the past year, GTBP or VTGN?
GTBP returned +451.85% over the past 12 months, compared with -93.88% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.